Phase 3 study of digital remote monitoring of patients treated with oral agents for metastatic cancer

Strategies that individualize the care of cancer patients receiving oral agents offer opportunities to improve treatment adherence and patient care. The phase 3 CAPRI study at Gustave Roussy (Villejuif, France) evaluated a nurse navigator-led follow-up system with a web portal-smartphone application in patients receiving oral medications for metastatic cancer. Compared to usual care, the intervention on top of usual care resulted in higher relative dose intensity (93.4% versus 89.4%; p=0.04), improved patient experience (PACIC score 2.94 versus 2.67; p=0.01), less days of hospitalization (2.84 versus 4.44 days; p=0.02), and less treatment-related grade ≥ 3 toxicities (27.6% versus 36.9%; p=0.02). The authors conclude that patient-centered care through remote monitoring of symptoms and treatment may improve patient outcomes and experience.